Northwest Biotherapeutics, Inc.
NWBO
$0.2074
-$0.0026-1.24%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.18% | 8.84% | 25.89% | 35.69% | -235.93% |
| Total Depreciation and Amortization | 15.94% | 22.37% | 5.40% | 15.53% | 34.66% |
| Total Amortization of Deferred Charges | -25.58% | -14.78% | -4.69% | -14.40% | -0.93% |
| Total Other Non-Cash Items | -37.95% | -47.35% | -58.29% | -66.91% | 118.77% |
| Change in Net Operating Assets | -38.83% | -117.56% | -105.53% | -151.26% | 52.51% |
| Cash from Operations | -18.16% | -24.63% | -7.36% | -1.63% | 17.48% |
| Capital Expenditure | 73.86% | 67.82% | 43.91% | -18.44% | -125.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 73.86% | 67.82% | 43.91% | -18.44% | -125.66% |
| Total Debt Issued | 28.88% | 109.98% | 73.32% | 308.35% | 19.32% |
| Total Debt Repaid | -296.76% | -4.67% | 82.08% | 92.99% | 96.65% |
| Issuance of Common Stock | 328.67% | 45.71% | -79.40% | -91.65% | -91.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -34.15% | -29.68% | -30.97% | -28.80% | 61.23% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -85.24% | -78.70% | 9,400.00% | -- | -- |
| Cash from Financing | 11.20% | 24.36% | 3.22% | 25.71% | -8.46% |
| Foreign Exchange rate Adjustments | -41.17% | 272.35% | -69.31% | -109.50% | -126.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.11% | 142.76% | -380.96% | 41.02% | -159.55% |
